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 Summary 
 Although high brain and acute leukemia, cytoplasmic (BAALC) expression is a 
well-characterized poor prognostic factor in acute myeloid leukemia (AML) patients, 
neither the exact mechanisms underlying overexpression of BAALC in 
leukemogenesis and drug resistance nor therapeutic approach against BAALC-high 
AML have been properly elucidated. Here we report that sustained activation of 
extracellular signal-regulated kinase (ERK) pathway, induced by the interaction of 
BAALC and mitogen-activated protein (MAP) kinase kinase kinase 1 (MEKK1), is 
found to be the hallmark of BAALC-high AML, which leads to accelerated cell cycle 
progression and development of chemoresistance. We demonstrated that BAALC 
promotes proliferation of leukemia cells by activating ERK pathway as an adaptor 
protein, which inhibits the interaction between ERK and mitogen-activated protein 
(MAP) kinase phosphatase 3 (MKP3/DUSP6). We also elucidated that BAALC 
induces ERK-mediated chemoresistance through up-regulation of ATP-binding 
cassette (ABC) transporter genes. Furthermore, BAALC holds Krüppel-like factor 4 
(KLF4) in the cytoplasm and inhibits KLF4-dependent differentiation of leukemia cells. 
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Consequently, MEK inhibition synergizes with KLF4 induction to suppress the growth 
of AML cells with high BAALC expression both in vitro and in vivo. Our data provide 
a molecular basis for the role of BAALC in regulating proliferation and differentiation 
of AML cells and highlight the unique dual function of BAALC as an attractive 
therapeutic target against BAALC-high AML.  
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Introduction 
 Acute myeloid leukemia (AML) is a clonal disorder characterized by differentiation 
arrest and accumulation of immature myeloid progenitors in the bone marrow, 
resulting in hematopoietic failure1. In clinical, AML is a highly heterogeneous disease, 
and responses to therapy can vary widely depending on patient- and disease-related 
factors. Current therapy for AML consists of chemotherapy and/or hematopoietic stem 
cell transplant (HSCT) for patients who meet eligibility requirements. Despite the 
curative potential of HSCT, however, the associated risks preclude many patients from 
undergoing this procedure. Of patients treated with intensive induction chemotherapy, 
a considerable proportion do not respond, relapse after initial responses. 
Disease-related risk factors for these treatment-resistant AML patients have 
historically been placed undue reliance on karyotype analysis, but recent advances in 
high-throughput molecular investigation using next-generation sequencers enabled 
more precise and rational grouping of high-risk AML in view of gene expressions and 
mutations. In spite of these recent proceedings in the management of AML, more than 
half of young adult and about 90 % of elderly patients still finally succumb to their 
disease2 and few effective treatments exist for these patients outside of HSCT. Thus, 
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novel therapeutic approaches different from conventional chemotherapies, based on 
deeper understanding in molecular mechanisms of poor-prognostic factors are urgently 
needed.  
 To date, several poor prognostic factors for AML have been reported, which include 
gene mutations in TET2, ASXL1 or DNMT3A3-5 and overexpression of ERG, EVI1, 
MN1 or BAALC6-9. BAALC was first reported as a novel gene implicated both in 
neuroectodermal and hematopoietic cell development10. In general, overexpression of 
BAALC is observed in one-forth of AML patients with normal karyotypes9, 11, 12, and 
recent reports have shown its adverse impact on the survival of AML patients across 
all karyotypes13. BAALC, located on human chromosome 8 at q22.3, encodes at least 8 
alternatively spliced transcripts in humans, and BAALC 1-6-8 is the major isoform 
expressed in hematopoietic cells10. In normal hematopoiesis, the expression of BAALC 
is limited to the immature fraction, i.e. CD34+ fraction rich in hematopoietic stem and 
progenitor cells14. In a large cohort of patients with AML, high BAALC expression 
was associated with expressions of stem cell markers11. From these facts, it is 
suggested that BAALC is related to immaturity of hematopoietic cells, but the precise 
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function of BAALC in leukemogenesis is poorly understood. 
 Aberrant activation of several oncogenic signaling cascades is implicated in AML 
pathogenesis15. Previous reports showed that Ras/Raf/mitogen-activated protein kinase 
(MEK)/extracellular signal-regulated kinase (ERK) pathway is activated in a 
significant proportion of AML patients16 and expected as a potential therapeutic 
target17. However, the antileukemic activity of MEK inhibitor monotherapy in the 
clinical settings has been modest18, which necessitates further elucidation of the full 
picture of the signaling networks, including spatial and temporal relationships of its 
components and factors that affect their interactions. Among them, Mitogen-activated 
protein kinase kinase kinase 1 (MEKK1) is necessary for efficient activation of ERK 
pathway not only as a protein kinase that phosphorylates MEK but as a scaffold protein 
of key elements in ERK pathway19. While previous reports have suggested a 
fundamental role of MEKK1 in anti-apoptotic function in myeloid cells and successive 
leukemogenesis20, 21, little has been reported on how molecular distribution of 
signaling factors around this essential scaffold protein affects oncogenic signaling 
cascade in AML.  
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 By contrast, ERK can trigger tumor suppressor pathways as well, such as cellular 
senescence, apoptosis and differentiation22-24 in a context-dependent manner. Among 
them, Krüppel-like factor 4 (KLF4), a member of Krüppel-like family transcription 
factors, is induced by ERK activation and mediates growth inhibition in human colon 
cancer cells25. Although KLF4 has been shown to enhance stem-cell like properties as 
one of four iPS factors26, it has been drawing attention in AML as an essential factor 
for monocytic differentiation27. Furthermore, KLF4 has been reported to possess 
growth-inhibitory properties in CDX2-driven AML28. Based on these findings, 
anticancer drugs that augment the effect of KLF4 have been newly developed and 
investigated in clinical and preclinical settings29-32. Although promising results from 
these studies highlight KLF4 as a potential therapeutic target for many malignancies 
including AML, given the effect of KLF4 is highly context-dependent33, precise 
characterization of KLF4 function in each setting is mandatory for proper therapeutic 
targeting.  
 In this study, we aimed to investigate the molecular basis of BAALC in leukemia cell 
proliferation and the therapeutic target for BAALC-high AML. We demonstrate here 
 8 
that through interactions with MEKK1 and KLF4, BAALC potentiates oncogenic ERK 
pathway while inhibiting ERK-dependent differentiation. This study could also 
determine whether concurrent MEK inhibition and KLF4 induction would be 
legitimate therapeutic targets for BAALC-high AML.  
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Materials and Methods. 
 
Mice 
NSG mice were purchased from the Jackson Laboratory. Littermates were used as 
controls in all experiments. All animal experiments were approved by The University 
of Tokyo Ethics Committee for Animal Experiments and strictly adhered to the 
guidelines for animal experiments of The University of Tokyo.  
 
Plasmids and expression constructs 
For lentiviral expression of each protein, we cloned cDNA construct of CA-MEK1, 
MEKK1, MKP3, KLF4, BAALC into CSII-EF-MCS-IRES2-Venus, 
CSII-EF-MCS-IRES2-hKO1, and CSIV-TRE-Ubc-KT vectors. Deletion mutants of 
BAALC, KLF4 and MEKK1 were produced by PCR-based mutagenesis from full 
length BAALC 1-6-8, KLF4 and MEKK1. Each mutant was designed as indicated in 
the body text, and cloned into MYC-tagged, FLAG-tagged, His-tagged or HA-tagged 
pcDNA3 expression vectors respectively. All of the PCR products were verified by 
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DNA sequencing. PCR primers used for the generation of each deletion mutant are 
listed in Table 1. 
 
Production and transduction of retrovirus and lentivirus 
To obtain retroviral supernatants, platinum-A (Plat-A) packaging cells were transiently 
transfected with each retrovirus vector by polyethylenimine (PEI, Sigma-Aldrich), and 
the viral supernatants were collected 48 hours after transfection and used immediately 
for infection. Virus was transduced to the objectives via retronectin-coated plates 
(clontech) for 48-72 hours, and transduced cells were sorted by flow cytometer Aria III 
(BD Biosciences). For the production of lentivirus supernatants, HEK293T cells were 
transiently co-transfected with lentivirus vectors, psPAX2 and pMD2.G. 
 
Yeast two-hybrid screening 
Yeast two-hybrid screening was performed with the Matchmaker Gold 
Yeast Two-Hybrid System (Clontech). Human BAALC 1-6-8 cDNA was used as bait 
and cloned into the pGBKT7 vector in frame with the GAL4 DNA-binding 
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domain (pBD-BAALC). Yeast Y2H GOLD cells were transformed with pBD-BAALC, 
subsequently mated to the purchased library strain transformed with a universal human 
cDNA library (Clontech cat. No. 630480). Interaction was confirmed as described in 
the Yeast Protocol Handbook (Clontech). After extraction of plasmids from positive 
clones, inserted cDNA was sequenced by 3130xL Genetic Analyzer (Applied 
Biosystems) and identical alignment was computationally searched by BLAST (Basic 
Local Alignment Search Tool, National Library of Medicine). 
 
Analysis of protein phosphorylation 
HEK293T cells were transiently transfected with 12 µg of pcDNA3-6xMYC-Mock or 
pcDNA3-6xMYC-BAALC vectors by PEI. Forty-eight hours after transfection, cells 
were serum-starved for 4 hours before stimulated by EGF at 10 ng/mL for 30 minutes, 
then harvested. After subsequent protein extraction, phosphorylated status of each 
cytoplasmic signaling (MAPK pathway, PI3K/AKT pathway, JAK/STAT pathway and 
NF-B pathway)-related molecule was examined by immunoblot analysis. 
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Immunoblotting 
Cells were washed twice with ice cold PBS and harvested in protein lysis buffer [50 
mM Tris (pH 7.4), 100 mM NaCl, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM β-glycerophosphate, 2.5 mM sodium pyrophosphate, 1mM Na3VO4, 1x 
protease inhibitor (Roche) and PhosSTOP (Roche)]. Whole cell extracts were resolved 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto 
polyvinylidene difluoride membranes. Membranes were probed with the following 
antibodies: anti-ERK, anti-phospho-ERK (Thr202/Tyr204), anti-MEKK1, anti-MKP3, 
anti-β-actin, anti-histone H3, anti-p90RSK, anti-phospho-p90RSK, anti-p38, 
anti-phospho-p38, anti-NF-κB, anti-phospho-NF-κB, anti-AKT, anti-phospho-AKT, 
anti-MYC-tag, anti-A-Raf, anti-phopho-A-Raf, anti-B-Raf, anti-phospho-B-Raf, 
anti-c-Raf, anti-phospho-c-Raf, anti-mTOR, anti-phospho-mTOR, anti-Raptor, 
anti-Rictor (Cell Signaling Technology), anti-JNK/SAPK1, anti-phospho- JNK/SAPK1, 
anti-JAK2, anti-phospho-JAK2, anti-STAT1, anti-phospho-STAT1, anti-STAT3, 
anti-phospho-STAT3, anti-STAT5, anti-phospho-STAT5, anti-STAT6, 
anti-phospho-STAT6 (BD pharmingen) and HRP-conjugated anti-FLAG-tag (Sigma 
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Aldrich) antibodies. For secondary antibodies, anti-rabbit IgG, or anti-mosue IgG, 
HRP-linked antibodies (Cell Signaling Technology) were used. Blots were detected 
using an ImmunoStar Zeta (Wako Pure Chemical Industries) and an LAS-3000 image 
analyzer (Fujifilm), as recommended by the manufacturers. Protein levels were 
quantified with ImageJ software (NIH). To obtain nuclear and cytoplasmic extracts, an 
Active Motif Nuclear Extract Kit was used according to the manufacturer’s 
instructions. 
 
Co-immunoprecipitation (CoIP) assay 
pcDNA3-3xFLAG-KLF4, pcDNA3-6xMYC-Mock, pcDNA3-6xMYC-BAALC, 
pcDNA3-3xFLAG-MEKK1, pcDNA3-6xHis-MKP3, deletion mutants of 
6xMYC-tagged BAALC, 3xFLAG tagged KLF4 and 3xFLAG-tagged MEKK1 were 
transiently transfected to HEK293T cells and cultured for 48 hours. Cells were lysed in 
cell lysis buffer, and the lysates were clarified by centrifugation. Cell extracts were 
pre-cleared with sepharose G protein beads (Sigma-Aldrich) at 4  for 1 hour, and 
then mixed with primary antibody (anti MYC-tag, anti HA-tag and anti FLAG-tag 
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antibodies), rocked at 4   for over night. Immune complexes were 
immunoprecipitated by sepharose G protein beads next day. Beads were washed by 
Tris-Acetate-EDTA (TAE) buffer for 5 times. Bound proteins were eluted with hot 
SDS loading buffer and were resolved by SDS-PAGE, then protein-protein interaction 
was examined by immunoblotting.  
 
Time-lapse IP assay 
pcDNA3-6xMYC-Mock or pcDNA3-6xMYC-BAALC vectors were transiently 
transfected to HEK293T cells by PEI. Cells were starved for four hours, then 
stimulated by EGF at 10 ng/mL for indicated time (0 min, 15 min, 30 min, 60 min) just 
before ice-cold PBS wash x2, then lysed immediately in lysis buffer [50 mM Tris (pH 
7.4), 100 mM NaCl, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1x protease 
inhibitor (Roche)]. Extracted proteins were immunoprecipitated by anti-MYC-tag 
antibody or anti-ERK antibody with sepharose G protein beads.  Protein-protein 
interaction was examined by immunoblotting. 
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In vitro pull-down assay 
pcDNA3-6xMYC-Mock, pcDNA3-6xMYC-BAALC, pcDNA3-6xHis-KLF4-Δ2 and 
pcDNA3-HA-MEKK1-Δ4 were transiently transfected to HEK293T cells and cultured 
for 48 hours before lysed. Expressed proteins were purified by c-MYC tagged Protein 
mild purification kit or His tagged Protein mild purification kit or HA tagged Protein 
mild purification kit (BML) according to the manufacturer’s instructions. Purification 
efficiency was checked by coomassie brilliant blue stains. Samples were mixed in 
binding buffer (50 mM Tris-HCl, 250 mM NaCl, 0.05 % Nonidet P-40, 30 mM MgCl2, 
pH 7.4) with protease inhibitor mixture (4 µg/mL) for 2 hours at 4 °C, then anti 
MYC-tag antibody was added before immunoprecipitation with sepharose G protein 
beads. Beads were washed by TAE buffer twice, then proteins bound to beads were 
resolved by SDS-PAGE. Protein-protein interaction was checked with 
immunoblotting. 
 
Cell culture 
HEK293T and Plat-A cells were cultured in DMEM-10 % heat inactivated FCS at 
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37 °C, 5 % CO2. Human leukemia cell lines Kasumi-1, OCI-AML2, MV4-11 and HEL 
cells were cultured in RPMI1640-10% heat inactivated FCS at 37 °C, 5 % CO2. Bone 
marrow cells of patient samples were maintained in RPMI1640 plus 20 % heat 
inactivated FCS supplemented with cytokines of IL-3, hSCF, FLT3L and MGDF 
(Wako Pure Chemical Industries) at 100 ng/mL.  
 
Cell growth curve 
To assess cell proliferation, 1 × 105 cells of AML cell lines and human primary bone 
marrow cells were counted and transferred to 6-well plate with 4mL medium. Cell 
number was counted every other day. 
 
Real-time quantitative PCR (qRT-PCR).  
Total RNA was isolated with RNeasy mini kit (Qiagen) and reverse transcribed with 
Reverse script kit (TOYOBO) to generate cDNA. Real-time quantitative polymerase 
chain reaction (PCR) was carried out with LightCycler480 (Roche) according to the 
manufacturer's instructions. The results were normalized to GAPDH levels. Relative 
 17 
expression levels were calculated using the 2-ΔΔCt method. Primers used for 
qRT-PCR were listed in Table 1. 
 
siRNA interference 
Specific shRNAs targeting human BAALC were designed and cloned into 
pSIREN-RetroQ-ZsGreen vectors (Clontech). Control shRNA is a nonfunctional 
construct targeting luciferase (sh_Luc.). The target sequences were provided in Table 
2. 
 
Immunofluorescence assay 
For Kasumi-1 cells, a total of 1 × 104 to 5 × 104 cells were cytospun onto glass slides. 
The cells were fixed with 3.7 % formaldehyde in PBS for 30 minutes, permeabilized 
by 0.2 % Triton X in PBS for 10 minutes, and blocked with 1 % BSA in PBS for 60 
minutes. Then, the slides were incubated with rabbit anti–KLF4 antibody (1:100 
dilution; Cell Signaling Technology) overnight at 4 °C, followed by incubation with 
Alexa Fluor 594 goat anti-rabbit IgG (1:250 dilution; Invitrogen) and DAPI (1:1,000 
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dilution; Invitrogen) for 90 minutes. Cells were gently washed by PBS, then they were 
treated with ProLong Gold Antifade Reagent (Invitrogen). Images were acquired using 
an Olympus FluoView FV10i confocal microscope with a × 60 objective oil immersion 
lens. For HEK293T cells, a total of 1 × 104 to 5 × 104 cells were cultured on glass 
slides transiently transfected with pcDNA3-3xFLAG-KLF4 and 
pcDNA3-6xMYC-BAALC or Mock vectors before fixation and permeabilization. 
Each slide was incubated with rabbit anti–KLF4 antibody (1:100 dilution; Cell 
Signaling Technology) or mouse anti-MYC-tag antibody (1:100 dilution; Cell 
Signaling Technology), followed by incubation with Alexa Fluor 647 goat anti-rabbit 
IgG (1:250 dilution; Invitrogen) or Alexa Fluor 488 goat anti-mouse IgG (1:250 
dilution; Invitrogen) and DAPI (1:1,000 dilution).  
 
Cell cycle and apoptosis assay 
For cell cycle analysis, cells were fixed with fixation buffer and permeabilized with 
permeabilization wash buffer (BioLegend) before incubated in PBS with 3 % heat 
inactivated FCS, DAPI 1:1000 and 100 µg/mL RNAseA until flow cytometry analysis. 
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For apoptosis assay, cell apoptosis was determined by Annexin V Apoptosis Detection 
Kit APC (eBioscience Inc.). Approximately 2 × 105 cells from each experimental 
group were washed with PBS and then suspended by annexin-binding buffer. 
Subsequently, 5 uL annexin V was added to each sample. Incubated for another 30 min, 
the cells were diluted by buffer and stained with DAPI just before analyzed with flow 
cytometry. 
 
Flow cytometry 
Isolation of CD34+/CD38- fraction from human normal or leukemic bone cells and 
isolation of leukemia cell lines transduced with immunofluorescent color markes of 
GFP, Kusabira-Orange and Venus were performed using FACSAria III (BD) cell 
sorter. For isolation of CD34+/CD38- fraction from human primary bone marrow cells, 
FITC-conjugated anti-human CD34, and PE-conjugated anti-human CD38 antibodies 
were used (eBioscience). For checking monocytic differentiation state of leukemia 
cells, Biotin-conjugated anti-human CD11b or CD14 and Streptavidin-APC 
(eBioscience) were used. Analysis was performed using FlowJo software (Tree Star 
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Inc.). 
 
IC50 evaluation 
AML cell lines were grown in RPMI 1640 plus 10 % heat inactivated FCS. For the 
growth inhibition assay, cells were placed at a density of 1 × 105 cells/mL. Different 
concentrations of U0126 were added to the media. Cell viability was assessed by 
counting the number of trypan blue excluding cells 4 days after starting culture. The 
doses that inhibited 50 % proliferation were analyzed by the median-effect method34.  
 
Xenograft mouse model 
A xenograft mouse model of human AML with high expression of BAALC was 
developed using NSG mice. Before transplantation, NSG mouse was treated with i.p. 
injection of cyclophosphamide 100 mg/kg/day for 2 days. At day 0 and day 1, 5 × 106 
cells/body of Kasumi-1 cells transduced with indicated viruses were i.v. injected. 
Peripheral blood (PB) was collected twice a week and chimerism was checked by flow 
cytometer. Once PB chimerism of leukemia cells exceeded 1 %, treatment either by 
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U0126 (25 µmol/kg/week i.p.) or doxycycline (diluted in drinking water at 1 g/L+3 % 
sucrose) was started. 
 
Statistics 
Statistical significance of differences between groups was assessed with a 2-tailed 
unpaired Student’s t test. Equality of variances in two populations was calculated with 
F-test. Differences were considered statistically significant at a P value of less than 
0.05. In leukemia cell transplantation experiments, the overall survival of mice is 
depicted by a Kaplan-Meier curve. Survival between groups was compared using the 
log-rank test. To measure the correlation between BAALC mRNA expression and 
sensitivity to MEK inhibitor (U0126) in human AML cell lines and patients samples, 
the Spearman’s rank correlation coefficient was used. 
 
Study approval 
BM cells derived from 80 patients with AML were obtained from the Department of 
Hematology and Oncology of the University of Tokyo Hospital. Seven bone marrow 
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cells from patients diagnosed with lymphoid neoplasia without bone marrow invasion 
were used as normal controls. The study was approved by the ethics committee of the 
University of Tokyo, and written informed consents were obtained from all patients 
whose samples were collected.  
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Results 
 
BAALC promotes leukemia cell expansion. 
 We first examined the expression levels of BAALC in CD34+ CD38- fraction of 
primary human bone marrow samples from control subjects and AML patients and in 
four AML cell lines. CD34+ CD38- AML cells showed five-fold higher BAALC than 
control subjects (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison of BAALC expressions in human bone marrow cells and AML cell 
lines. 
Relative BAALC expressions in primary human bone marrow cells from AML patients 
(n = 80), control subjects (n = 7) and AML cell lines (n = 4). Values are normalized to 
BAALC expression in control subjects.  
Data are mean SEM values. * P < 0.05, ** P < 0.01. 
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 BAALC was higher even in human primitive CD34+ CD38- AML cells compared to 
normal CD34+ CD38- cells which are rich in hematopoietic progenitor cells (Figure 2). 
 
 
 
 
 
 
Figure 2. Comparison of BAALC expressions in immature fraction of human bone 
marrow cells from AML patients and control subjects. 
Relative BAALC expressions in CD34+ CD38- fraction of primary human bone marrow 
cells from AML patients (n = 7), control subjects (n = 7). Values are normalized to 
BAALC expression in primary human whole bone marrow cells from control subjects. 
Data are mean SEM values. ** P < 0.01. 
 
 Taken into account that high BAALC expression represents cases belonging to the 
upper quartile of BAALC expression in a cohort of AML patients9, among four AML 
cell lines, Kasumi-1 and OCI-AML2 showed comparable BAALC levels as 
BAALC-high AML patient samples, while BAALC expressions were low in HEL and 
MV4-11. From this finding, hereafter we used Kasumi-1 as BAALC-high leukemia 
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cells and HEL as BAALC-low cells (Figure 3A and 3B). 
 
 
 
 
 
 
 
Figure 3. Comparison of BAALC expressions in AML cell lines and immature fraction of 
human bone marrow cells. 
(A) Relative BAALC expressions in AML cell lines (n = 4). Values are normalized to BAALC 
expression in HEL cells. (B) Comparison of Relative BAALC expressions between 
CD34+CD38- primary AML cells (n = 7) and AML cell lines (n = 4). Values are normalized to 
BAALC expression in HEL cells. Data are mean ± SEM values. * P < 0.05.  
 
 When full-length of BAALC (1-6-8 form) was lentivirally transduced to HEL (Figure 
4A), they showed an increased proliferative capacity (Figure 4B) and accelerated cell 
cycle progression (Figure 4C and 4D), while apoptotic status was not altered (Figure 
4E and 4F).  
A B 
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Figure 4. Overexpression of BAALC promotes proliferation of HEL cells. 
(A) Relative BAALC expressions in HEL cells transduced with BAALC or control vector. 
Values are normalized to BAALC expression in HEL cells transduced with control vector. (n = 
3) (B) Growth curve of HEL cells transduced with BAALC or control vector (mock). (n = 3) 
(C and D) Cell cycle was assessed with flow cytometry in HEL cells transduced with BAALC 
or control vector. (C) Representative flow cytometric data showing cell cycle distributions. (D) 
Cumulative data showing percentage of S and G2/M phase (n = 3). (E and F) Apoptotic status 
in HEL cells transduced with BAALC or control vector. (E) Representative flow cytometric 
A 
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data of Annexin V and DAPI staining. (F) Cumulative data of the frequency of early apoptotic 
cells (Annexin V+ DAPI-) (n = 3). Data are mean ± SEM values. * P < 0.05.  
 
 On the other hand, knockdown of BAALC using retroviral short hairpin RNA 
(shRNA) in Kasumi-1 cells (Figure 5A) partially blocked proliferation (Figure 5B) and 
cell cycle progression (Figure 5C and Figure 5D) without any effects on apoptosis 
(Figure 5E and 5F).  
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
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Figure 5. Knockdown of BAALC suppresses proliferation of Kasumi-1 cells. 
(A) Relative BAALC expressions in Kasumi-1 cells transduced with control (sh_Luc.) or 
BAALC (sh_BAALC) shRNA (n = 3). Values are normalized to BAALC expression in control 
shRNA-transduced cells. (B) Growth curve of Kasumi-1 cells transduced with sh_Luc. or 
sh_BAALC (n = 3). (C and D) Cell cycle was assessed with flow cytometry in Kasumi-1 cells 
transduced with sh_Luc. or sh_BAALC. (C) Representative flow cytometric data showing cell 
cycle distributions. (D) Cumulative data showing percentage of S and G2/M phase (n = 3) (E 
and F) Apoptotic status in Kasumi-1 cells transduced with sh_Luc. or sh_BAALC. (E) 
Representative flow cytometric data for Annexin V and DAPI staining. (F) Cumulative data of 
the frequency of early apoptotic cells (Annexin V+ DAPI-) (n = 3). Data are mean ± SEM 
values. * P < 0.05. 
D 
E 
F 
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 Knockdown of BAALC in Kasumi-1 cells also promoted monocytic differentiation as 
exemplified by higher expressions of differentiation-associated markers such as 
CD11b and CD14 than those of control cells (Figure 6A and Figure 6B). These results 
indicate that BAALC promotes proliferation, cell cycle progression of leukemia cells 
along with inhibition of leukemia cell differentiation.  
 
 
 
 
 
 
 
 
 
 
Figure 6. Knockdown of BAALC promotes monocytic differentiation of Kasumi-1 cells. 
(A) Representative flow cytometric data showing CD11b and CD14 expressions in sh_Luc. or 
sh_BAALC-transduced Kasumi-1 cells. (B) Cumulative data of CD11b or CD14 positive cells 
(n = 3). Data are mean ± SEM values. * P < 0.05, ** P < 0.01.  
A 
B 
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MEKK1 and KLF4 are novel interacting partners of BAALC.  
 To gain insight into molecular functions of BAALC, interacting partners of BAALC 
were explored with a yeast two-hybrid system on a proteome-wide scale (Figure 7A). 
Using BAALC as bait and a cDNA library from adult human tissues as prey, we 
identified eight possible interacting molecules (Figure 7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 7. Screening binding partners of BAALC by yeast two-hybrid method. 
(A) Schematic abstract of yeast two-hybrid screening. Human BAALC 1-6-8 was used as bait 
and a cDNA library from adult human tissues as prey. (B) Potential binding partners of 
BAALC detected by yeast two-hybrid screening. Coded sequences contained in prey vectors 
were shown for MEKK1 and KLF4. 
  
 Among them, we focused on MEKK1 and KLF4, both of which are known to have 
substantial roles in Ras/Raf/MEK/ERK pathway, one of pivotal oncogenic signaling 
cascades in AML19, 35. MEKK1 works as a scaffold protein as well as a kinase in 
MAPK cascade, and specifically potentiates ERK pathway by recruiting Raf, MEK 
and ERK19. KLF4 is a downstream target of ERK, regulated by direct interaction 35. To 
validate the interactions between BAALC and MEKK1 or KLF4, we performed 
co-immunoprecipitation (CoIP) assay in HEK293T cells. Intriguingly, BAALC bound 
to MEKK1 more tightly in the presence of epidermal growth factor (EGF), a potent 
ERK activator (Figure 8A and 8B).  
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Figure 8. BAALC interacts with MEKK1 stimulation dependently. 
(A) Relative BAALC expressions in HEK293T cells transiently transfected with BAALC or 
control vector. Values are normalized to BAALC expression in HEL cells transduced with 
control vector. (n = 3) 
(B and C) Interaction between BAALC and MEKK1 was examined by 
co-immunoprecipitation assay. HEK293T cells were co-transfected with His-tagged MEKK1 
and MYC-tagged BAALC. Cells were stimulated by EGF (10 ng/mL) or dimethyl sulfoxide 
(DMSO) for 30 minutes, and immunoprecipitated by anti-MYC tag antibody followed by 
blotting with anti-HA tag antibody (B) or immunoprecipitated by anti-HA tag antibody 
followed by blotting with anti-MYC tag antibody (C). 
 
 On the other hand, BAALC-KLF4 complex was formed independently of stimulation 
(Figure 9A and 9B).  
B C 
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Figure 9. BAALC interacts with KLF4 stimulation independently. 
Interaction between BAALC and KLF4 was examined by co-immunoprecipitation assay. 
HEK293T cells were cotransfected with FLAG-tagged KLF4 and MYC-tagged BAALC. Cells 
stimulated by EGF were immunoprecipitated by anti-MYC tag antibody followed by blotting 
with anti-FLAG tag antibody (A) or immunoprecipitated by anti-FLAG tag antibody followed 
by blotting with anti-MYC tag antibody (B).  
 
 Protein-protein interactions between BAALC and MEKK1 or KLF4 were further 
affirmed by in vitro pull-down assays using purified proteins obtained from 
mammalian cells (Figure 10A and 10B).  
 
 
 
 
 
 
A B 
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Figure 10. Direct interaction of BAALC with MEKK1 and KLF4 is confirmed by in vitro 
pull-down assay. 
(A) Interaction between BAALC and MEKK1 was assessed by in vitro pull-down assay. To 
obtain soluble recombinant protein, shortened form of MEKK1 (MEKK1-Δ4) was utilized (see 
Figure 12). Purified MYC-tagged BAALC and HA-tagged MEKK1-Δ4proteins were mixed 
and immunoprecipitated by anti-MYC tag antibody followed by blotting with anti-HA tag 
antibody. (B) Interaction between BAALC and KLF4 by in vitro pull-down assay. To obtain 
soluble recombinant protein, shortened form of KLF4 (KLF4-Δ2) was utilized (see Figure 12). 
Purified MYC-tagged BAALC and His-tagged KLF4-Δ2 proteins were mixed and 
immunoprecipitated by anti-MYC tag antibody followed by blotting with anti-His tag 
antibody. 
 
 These results illustrate that BAALC directly interact with MEKK1 in a 
stimulation-dependent, and with KLF4 in a stimulation-independent manner. 
 
N-terminal region of BAALC is necessary and sufficient for the interactions with 
MEKK1 and KLF4. 
 Next, we elucidated an essential binding region of each protein using a series of 
deletion mutants of BAALC, MEKK1 and KLF4. CoIP assay revealed that N-terminal 
region of BAALC (amino acids 1-35) was an indispensable prerequisite for its binding 
to MEKK1 and KLF4 (Figure 11A and 11B).  
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Figure11. N-terminal region of BAALC interacts with MEKK1 and KLF4. 
(A) The binding site of BAALC with MEKK1. HA-tagged MEKK1 and MYC-tagged deletion 
mutants of human BAALC were cotransfected into HEK293T cells. Immune complexes were 
precipitated by anti-MYC tag antibody and blotted by anti-HA tag antibody. (B) The binding 
site of BAALC with KLF4. FLAG-tagged KLF4 and MYC-tagged deletion mutants of 
BAALC were cotransfected into HEK293T cells. Immune complexes were precipitated by 
anti-MYC tag antibody and blotted by anti-FLAG tag antibody. 
 
 Notably, this N-terminal region of BAALC is conserved across all mammals 
expressing BAALC, indicating the functional importance of this region10, 36. HEL cells 
expressing deletion mutants of BAALC harboring N-terminal 1-35 amino acid 
sequence (	 1, Δ2) showed comparable proliferation (Figure 12A) and cell cycle 
progression (Figure 12B and 12C) to cells expressing full-length BAALC. By contrast, 
A B 
 36 
BAALC mutants lacking N-terminal domain (Δ3, Δ4) had no effect on proliferation 
and cell cycle progression, underscoring a fundamental role of this region for 
proliferative capacity of BAALC. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. N-terminal region of BAALC is necessary and sufficient for leukemogenic 
function of BAALC. 
(A) Growth curve of HEL cells transduced with a series of deletion mutants of BAALC. 
Comparison was made between each BAALC-expressing cells and mock-transduced cells (n = 
3). (B and C) Cell cycle was assessed by flow cytometry in HEL cells transduced with each 
deletion mutant of BAALC. (B) Representative flow cytometric data showing cell cycle 
A 
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distributions. (C) Cumulative data showing % of cells in S and G2/M phase (n = 3).  
Data are mean ± SEM values. * P < 0.05. 
 
 Furthermore, it was found that C-terminal region of MEKK1 and KLF4 were 
necessary for their interactions with BAALC (Figure 13A and 13B).  
 
 
 
 
 
 
 
 
Figure 13. Binding sites in MEKK1 and KLF4 for BAALC 
(A) The binding site in MEKK1 for BAALC determined by CoIP assay. MYC-tagged BAALC 
and FLAG-tagged deletion mutants of MEKK1 were cotransfected into HEK293T cells. 
Immune complexes were precipitated by anti-MYC-tag antibody and blotted by anti-FLAG tag 
antibody. (B) The binding site in KLF4 for BAALC determined by CoIP assay. MYC-tagged 
BAALC and FLAG-tagged deletion mutants of KLF4 were cotransfected into HEK293T cells. 
Immune complexes were precipitated by anti-MYC-tag antibody and blotted by anti-FLAG tag 
antibody. 
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 MEKK1 has a kinase domain in its C-terminus and MEK1 interacts with this region37, 
suggesting that BAALC possibly modifies ERK pathway through interacting with 
C-terminus of MEKK1 and alter the docking of signaling molecules around MEKK1. 
Since KLF4 has a nuclear localization signal (NLS) motif in its C-terminus38, it is 
supposed that BAALC might affect nuclear localization of KLF4. These findings 
indicate that the N-terminal region of BAALC is essential for cell cycle progression 
and inhibiting differentiation of myeloid leukemia cells through interactions with 
C-terminal regions of MEKK1 and KLF4. 
 
BAALC prolongs ERK activation by inhibiting reassociation of an ERK-specific 
phosphatase MKP3. 
 Considering that MEKK1 and KLF4 are both involved in ERK pathway19, 35, we 
postulated that BAALC induces leukemia cell proliferation by potentiating MEK/ERK 
signaling. Using BAALC-overexpressing HEK293T cells, we found that BAALC 
specifically up-regulated the activities of ERK and its direct downstream target 
ribosomal protein S6 kinase, 90kDa (p90RSK)39, without affecting the phosphorylation 
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status of other upstream molecules of ERK (Figure 14A). The activities of other 
signaling pathways including PI3K-AKT, JAK-STAT, NF-B pathways were not 
altered by BAALC (Figure 14B), suggesting BAALC specifically affects the activity 
of ERK.  
 
 
 
 
 
 
 
 
 
Figure 14. Screening phosphorylation status of cytoplasmic signal transduction-related 
molecules. 
(A) Immunoblotting of phosphorylated proteins of MAPK signaling cascade in HEK293T cells 
transfected with MYC-tagged BAALC or control vector. Cells were stimulated with EGF (10 
ng/mL) for 30 minutes. (B) Immunoblotting of phosphorylated proteins of PI3K/AKT, 
JAK-STAT and NF-κB pathways. 
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 Similarly, HEL cells transduced with BAALC showed prolonged ERK activation 
compared to the control cells (Figure 15A), while knockdown of BAALC decreased 
the ERK activation in Kasumi-1 cells (Fig. 15B).  
 
 
 
 
 
Figure 15. BAALC up-regulates activity of ERK pathway. 
(A) Immunoblotting of phosphorylated ERK in HEL cells transduced with MYC-tagged 
BAALC. Cells were stimulated with PMA (100 ng/mL) for 6 hours. (B) Immunoblotting of 
phosphorylated ERK in Kasumi-1 cells transduced with sh_BAALC or sh_Luc. Cells were 
stimulated with PMA (100 ng/mL) for 6 hours. 
 
 A time lapse analysis of ERK phosphorylation after phorbol myristate acetate (PMA) 
treatment revealed that not a maximal intensity but a duration of ERK activation was 
affected by BAALC in HEL cells (Figure 16).  
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Figure 16. BAALC induces prolonged up-regulation of ERK pathway. 
Immunoblotting of phosphorylated ERK in HEL cells transduced with BAALC. Cells were 
stimulated with PMA (100 ng/mL) for the indicated time periods. 
 
 As shown above, BAALC potentiated ERK phosphorylation without influencing 
kinase activity in the upstream of ERK, although it has no known kinase or 
phosphatase sequence motifs14. In addition, MEKK1 scaffolds components of its own 
signaling cascade, and thus positional relationship of these molecules around MEKK1 
are fundamental in efficient ERK activation. These facts made us hypothesize that 
BAALC contribute to the sustained ERK phosphorylation by hindering the interaction 
between ERK and mitogen-activated protein kinase phosphatase 3 (MKP3/ DUSP6 
dual specificity phosphatase 6), an ERK-specific phosphatase which mediates 
deactivation of ERK signaling40. To test this hypothesis, we conducted a time lapse 
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analysis of CoIP assay, in which HEK293T cells transiently overexpressing BAALC 
were harvested at the indicated time points after stimulation with EGF and analyzed 
for the interaction between BAALC, ERK, MKP3 and MEKK1. BAALC bound to 
MEKK1 immediately after EGF stimulation, strongest at around 30 minutes after 
stimulation (Figure 17A and 17B).  
 
 
 
 
 
Figure 17. BAALC interacts with MEKK1 stimulation dependently.  
(A) Interaction between BAALC and MEKK1. HEK293T cells were cotransfected with 
HA-tagged MEKK1 and MYC-tagged BAALC or MYC-tagged control vector. Cells were 
stimulated with EGF (10 ng/mL) for the indicated time periods. Immune complexes were 
precipitated by anti MYC-tag antibody and blotted by anti HA-tag antibody.  (A) 
Representative immunoblot showing BAALC-bound MEKK1. (B) Cumulative data of the 
amount of MEKK1 bound to BAALC as represented in (E). Values were normalized to that of 
BAALC overexpressing HEL cells at 0 minute after EGF stimulation (n = 3) 
Data are mean ± SEM values. * P < 0.05. 
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 As for the interaction between ERK and MKP3, EGF treatment rapidly induced 
dissociation of MKP3 from ERK, followed by MKP3 reassociation with ERK after 30 
minutes of stimulation in control cells. On the contrary, in BAALC-overexpressing 
cells, the recruitment of MKP3 to ERK at 30 minutes was hindered along with the 
stimulation-dependent BAALC-MEKK1 interaction up to 60 minutes after stimulation 
(Figure 18A and 18B).  
 
 
 
 
 
Figure 18. BAALC blocks reassociation of MKP3 and ERK. 
(A) Interaction between ERK and MKP3. HEK293T cells were cotransfected with 
FLAG-tagged MKP3 and MYC-tagged BAALC or MYC-tagged control vector. Cells were 
stimulated with EGF (10 ng/mL) for the indicated time periods. Immune complexes were 
precipitated by anti-ERK antibody and ERK-bound MKP3 was detected by anti FLAG-tag 
antibody.  (B) Cumulative data of the amount of MKP3 bound to ERK as represented in (A). 
Values were normalized to that of mock-transduced HEK293T cells taken at 15 minutes after 
EGF stimulation (n = 3). Data are mean ± SEM values. * P < 0.05. 
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 The extent of ERK phosphorylation was inversely correlated to the intensity of the 
ERK-MKP3 interaction, underscoring the importance of MKP3 in determining ERK 
activity (Figure 19A and 19B).   
 
 
 
 
 
Figure 19. Phosphorylation of ERK is positively regulated by the interaction of BAALC 
and MEKK1. 
Time lapse analysis of ERK activation in HEK293T cells transfected with BAALC or control 
vector. Cells were stimulated with 10 ng/mL EGF for the indicated time periods. (A) 
Immunobloting of phosphorylated ERK. (B) Cumulative data of the amount of phosphorylated 
ERK. Values are normalized to control sample taken at 0 minute after stimulation (n = 3). 
Data are mean ± SEM values. * P < 0.05. 
 
 To verify that BAALC promotes proliferation of leukemia cells by inhibiting the 
function of MKP3, we evaluated the effect of MKP3 overexpression on 
BAALC-induced cell proliferation in HEL cells. U0126, a potent and specific inhibitor 
of MEK41, inhibited proliferation in both control and BAALC-expressing HEL cells to 
a comparable level, completely abrogating the growth advantage conferred by BAALC 
(Figure 20).  
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Figure 20. Proliferative advantage of BAALC is canceled by MEK inhibition. 
Growth curve of HEL cells transduced with BAALC or control vector followed by treatment 
with U0126 (5 µM) or DMSO (n =3). Data are mean ± SEM values. * P < 0.05. 
 
 In addition, growth advantage of BAALC-expressing cells was reversed by forced 
expression of MKP3 (Figure 21A – 21C), suggesting that BAALC affects proliferative 
capacity of AML cells in a ERK-dependent manner.  
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Figure 21. BAALC and MKP3 competitively interact with ERK. 
(A) Immunobloting of phosphorylated ERK in HEL cells cotransduced with BAALC and 
MKP3. (B) Growth curve of HEL cells cotransduced with BAALC and MKP3 (n =3). (C) Cell 
cycle analysis (% of S and G2/M phase) of HEL cells cotransduced with BAALC and MKP3 
(n =3). Data are mean ± SEM values. * P < 0.05. 
 
 These results collectively suggest that BAALC interacts directly with MEKK1, an 
essential scaffold protein for ERK activation, and induces prolonged ERK activation 
by inhibiting reassociation of MKP3 to ERK (Figure 22). 
 
 
 
 
Figure 22. BAALC works as an adaptor protein in ERK pathway. 
Schematic representation of the function of BAALC in ERK pathway. Molecular dynamics 
around MEKK1 were depicted. Time after ERK pathway activation was classified into three 
phases, un-stimulated phase (before EGF stimulation), early phase (0 to 30 minutes after EGF 
stimulation) and late phase (60 minutes after EGF stimulation and thereafter). 
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BAALC induces drug resistance in AML cells through ERK activation. 
 High BAALC expression is clinically associated with overexpression of genes 
involved in drug resistance, lower complete remission rate and refractoriness to 
chemotherapy in AML cases11, 42. Given that ERK can exert its oncogenic activity 
through increasing resistance to chemotherapeutic drugs43, 44, we deduced that BAALC 
may lead to drug resistance via ERK pathway. ATP-binding cassette (ABC) proteins 
transport various molecules including incorporated cytotoxic agents across extra-and 
intra-cellular membranes and represent a major mechanism of drug resistance45. 
Among the superfamily of ABC transporters, ABCB1 (MDR1; multidrug resistance 
protein 1), ABCC1-5 (MRP1-5; multidrug resistance-associated protein-1-5) and 
ABCG2 (BCRP1; breast cancer resistance protein 1) are well-known downstream 
targets of ERK pathway46-48. To elucidate the role of BAALC-induced ERK activation 
in induction of drug resistance genes in BAALC-expressing cells, we treated AML 
cells with cytosine arabinoside (AraC), an essential component of AML treatment, and 
measured the mRNA expression of these ABC transporters. We found that additive 
BAALC expression in HEL cells potentiated the up-regulation of ABCB1, ABCC1, 
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ABCC4 and ABCG2 in response to AraC treatment (Figure 23).  
 
 
 
 
 
 
 
 
Figure 23. BAALC induces expression of ABC transporter genes. 
Expression levels of ABC transporters (ABCB1, ABCC1, ABCC4 and ABCG2) in HEL cells 
transduced with BAALC or control vector followed by treatment with AraC (1 µM) or DMSO 
for 48 hours. Values were normalized to that of mock-transduced HEL cells treated with 
DMSO (n = 3). Data are mean ± SEM values. * P < 0.05, ** P < 0.01. 
 
 When the half-maximal inhibitory concentrations (IC50) were assessed, in line with 
the high expression of resistance-related genes, BAALC-expressing cells were more 
resistant to AraC treatment (Figure 24).  
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Figure 24. BAALC induces resistance to AraC treatment in HEL cells. 
AraC sensitivity of HEL cells transduced with BAALC or control vector. Cells were treated 
with AraC at the indicated concentrations and cell viabilities were determined by trypan blue 
exclusion assays (n = 3). IC50 values of BAALC or mock overexpressing HEL cells are 
provided. Data are mean ± SEM values. 
 
 Up-regulation of these ABC transporters were abrogated in the presence of MEK 
inhibitor (Figure 25), indicating that BAALC-induced drug resistance is a 
MEK/ERK-dependent process.  
 
 
 
 
 
 
 
 
Figure 25.  BAALC-induced expression of ABC transporter genes is reverted by MEK 
inhibition. 
Expression levels of ABC transporters (ABCB1, ABCC1, ABCC4 and ABCG2) in HEL cells 
transduced with lentiviruses encoding BAALC followed by treatment with AraC (1 µM) or 
DMSO for 48 hours in the presence of U0126 (5 µM). Data was normalized to the result of 
BAALC transduced HEL cells with DMSO treatment (n = 3).  
Data are mean ± SEM values. * P < 0.05, ** P < 0.01. 
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 Consequently, MEK inhibitor overcame the chemoresistance of BAALC-expressing 
cells to AraC (Figure 26).  
 
 
 
 
 
Figure 26. MEK inhibition cancels BAALC-induced drug resistance in HEL cells. 
AraC sensitivity of HEL cells transduced with BAALC or control vector in the presence of 
U0126 (5 µM). Cells were treated with AraC at the indicated concentrations and cell viabilities 
were determined by trypan blue exclusion assays (n = 3). IC50 values of BAALC or mock 
overexpressing HEL cells are provided. Data are mean ± SEM values. 
  
 These results support the idea that BAALC induces drug resistance by up-regulating 
the expression of drug resistance genes in an ERK-dependent way, which also can be 
targeted by MEK inhibitor. 
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Monocytic differentiation induced by constitutive activation of the ERK pathway 
is dependent on nuclear expression of KLF4. 
 To address whether the growth-promoting effect of BAALC overexpression on 
leukemia cells was dependent on the ERK pathway, the constitutive active form of 
MEK1 (CA-MEK1, S218E/S222E) was transduced into HEL cells. In clear contrast to 
the case of BAALC overexpression, CA-MEK1 decreased cell proliferation (Figure 
27A) and induced monocytic differentiation (Figure 27B and 27C), despite comparable 
phosphorylation of ERK (Figure 27D).  
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Figure 27. Phenotypic discrepancy between BAALC and CA-MEK1. 
(A) Growth curve of HEL cells transduced with BAALC, CA-MEK1 or control vector (n = 3). 
(B) Representative flow cytometric data showing CD11b and CD14 expressions in Kasumi-1 
cells transduced with BAALC, CA-MEK1 or control vector. (C) Cumulative data of the 
percentage of CD11b and CD14 positive cells (n = 3). (D) Immunoblotting of phosphorylated 
ERK in HEL cells transduced with BAALC, CA-MEK1 or control vector. Cells were 
stimulated by PMA (100 ng/mL) for 6 hours.  
Data are mean ± SEM values. * P < 0.05, ** P < 0.01.  
  
 To further investigate this phenotypic discrepancy, we focused on a biological 
function of KLF4, another interacting partner of BAALC, the expression of which is 
positively regulated by ERK in tumor cells from several origins25, 49. Taken into 
account the involvement of KLF4 in monocytic differentiation of myeloid cells27, 50, it 
was supposed that KLF4 may have some role in ERK-independent action of BAALC. 
Given KLF4 exerts transcription activating potential in the nucleus as a transcription 
factor with zinc-finger motifs38, the amount of KLF4 in the nucleus is considered to be 
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of importance. When we compared the expression levels of KLF4 by immunoblotting, 
nuclear expression of KLF4 was increased in CA-MEK1-transduced HEL cells, 
accompanied by increase of KLF4 in whole cell lysates (Figure 28).  
 
 
 
 
Figure 28. Constitutive activation of ERK pathway induces KLF4 accumulation in the 
nucleus. 
Immunoblotting of total and nuclear KLF4 in HEL cells cotransduced with KLF4 (sh_KLF4) 
and CA-MEK1. 
 
 When KLF4 was knocked down by shRNA in this context, CA-MEK1-induced 
growth arrest was reversed along with decreased KLF4 expression in the nucleus, 
although knockdown of KLF4 had little effect on the proliferative capacity in the 
absence of constitutive activation of ERK (Figure 29).  
 
 
  
 54 
 
 
 
 
 
Figure 29. Growth suppression of CA-MEK1 is canceled by KLF4 knockdown in HEL 
cells. 
Growth curve of HEL cells cotransduced with sh_KLF4 and CA-MEK1 (n = 3). 
Data are mean ± SEM values. * P < 0.05. 
 
 CA-MEK1-induced differentiation was also counteracted by KLF4 depletion assessed 
by flow cytometric analyses of monocyte differentiation markers (Figure 30A and 
30B).  
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Figure 30. CA-MEK1-induced monocytic differentiation of HEL cells is canceled by 
KLF4 knockdown. 
(A) Representative flow cytometric data showing CD11b and CD14 expressions in HEL cells 
cotransduced with sh_KLF4 and CA-MEK1. (B) Cumulative data of the frequency of CD11b 
and CD14 positive cells (n =3). Data are mean ± SEM values.* P < 0.05, ** P < 0.01. 
 
KLF4 knockdown also inhibited up-regulation of monocytic 
differentiation-related genes (CES1, CSF1R, MAFB) induced by CA-MEK1 (Figure 
31).  
 
 
 
 
 
 
 
 
Figure 31. CA-MEK1-induced expressions of monocytic differentiation-associated genes 
are reverted by KLF4 knockdown. 
Expressions of monocytic differentiation-associated genes (CES, CSF1R and MAFB) in HEL 
cells cotransduced with sh_KLF4 and CA-MEK1 (n = 3). Values were normalized to that of 
mock-transduced HEL cells. 
Data are mean ± SEM values.* P < 0.05, ** P < 0.01. 
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 Morphologic analysis revealed that CA-MEK1-expressing cells exhibited marked 
changes characterized by increased cell volume, typical folded nuclei with decreased 
nuclear/cytoplasmic ratio and vacuoles in the cytoplasm, consistent with monocytic 
phenotype. Simultaneous expression of KLF4 shRNA reversed CA-MEK1-induced 
morphological change (Figure 32).  
 
 
 
 
 
 
 
 
Figure 32. CA-MEK1-induced monocytic change is reverted by KLF4 knockdown. 
Representative images of May-Giemsa stained HEL cells cotransduced with sh_KLF4 and 
CA-MEK1 (scale bars, 50 µm). 
  
 These data indicates that sustained activation of ERK pathway induces monocytic 
differentiation in leukemia cells in a KLF4-dependent manner. 
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BAALC antagonizes increased KLF4 activity through ERK activation and 
inhibition of nuclear KLF4 localization.  
 Since BAALC- and CA-MEK1-overexpressing cells commonly showed prolonged 
ERK activation, we further investigated the difference between BAALC and 
CA-MEK1 in cell proliferation. When BAALC was transfected into HEK293T cells, 
immunofluorescence microscopy revealed that KLF4 translocated from nucleus to 
cytoplasm (Figure 33).  
 
 
 
 
 
 
 
Figure 33. BAALC overexpression drives translocation of KLF4 from the nucleus to the 
cytoplasm. 
Immunofluorescence images of KLF4 in HEK293T cells transduced with MYC-tagged 
BAALC or control vector (scale bars, 10 µm). 
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 On the contrary, knocking-down of BAALC in Kasumi-1 cells, had cytoplasmic 
KLF4 shift to nucleus (Figure 34).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Knockdown of BAALC induces translocation of KLF4 from the cytoplasm to 
the nucleus. 
Immunofluorescence images of KLF4 in Kasumi-1 cells transduced with sh_Luc. or 
sh_BAALC (scale bars, 10 µm). 
 
 Immunoblotting of nuclear extracts from these cells showed that the amount of KLF4 
in the nucleus was decreased by BAALC overexpression and increased by 
BAALC-knockdown, and the amount of cytoplasmic KLF4 inversely related to that of 
nuclear KLF4 (Figure 35A – 35D).  
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Figure 35. BAALC holds KLF4 in the cytoplasm and blocks its nuclear translocation. 
(A) Immunoblotting of KLF4 in the nuclear and cytoplasmic fractions of HEK293T cells 
transduced with MYC-tagged BAALC or control vector. (B) Cumulative data of the amount of 
KLF4 as represented in (A). Values were normalized to that of nuclear fraction from BAALC 
overexpressing HEK293T cells (n = 3). (C) Immunoblotting of KLF4 in the nuclear and 
cytoplasmic fractions of Kasumi-1 cells transduced with sh_Luc. or sh_BAALC. (D) 
Cumulative data of the amount of KLF4 as represented in (C). Values were normalized to that 
of nuclear fraction from control vector transduced Kasumi-1 cells (n = 3). 
Data are mean ± SEM values. * P < 0.05, ** P < 0.01. 
 
 When CD34+ CD38- bone marrow cells from AML patients were assessed for KLF4 
localization, BAALC-high cases (the upper quartile of BAALC expression) mainly 
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showed cytoplasmic KLF4, while KLF4 was proportionally distributed both in the 
nucleus and the cytoplasm in BAALC-low cases (the lower quartile) (Figure 36A and 
Figure 36B).  
 
 
 
 
 
 
 
Figure 36. BAALC blocks nuclear translocation of KLF4 in human AML bone marrow 
cells. 
(A) Immunofluorescence images of KLF4 in CD34+ CD38- bone marrow cells from AML 
patients. Representative images from two AML patients with high and low BAALC expression 
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were shown (scale bars, 10 µm). (B) Cumulative data of cytoplasm-nucleus ratio of KLF4 in 
CD34+ CD38- bone marrow cells from five AML patients with high and low BAALC 
expression respectively. Data are mean ± SEM values. ** P < 0.01. 
 
 To prove the hypothesis that BAALC inhibits ERK-mediated monocytic 
differentiation by relocating KLF4 from the nucleus to the cytoplasm, we examined 
whether the growth arrest with monocytic differentiation in CA-MEK1-expressing 
HEL cells could be overcome by additional BAALC expression. Indeed, BAALC 
overexpression in CA-MEK1-transduced HEL cells restored proliferative capacity 
(Figure 37).  
 
 
 
 
 
Figure 37. CA-MEK1-induced growth suppression of HEL cells is reverted by additional 
BAALC expression. 
Growth curve of HEL cells cotransduced with BAALC and CA-MEK1 (n = 3).  
Data are mean ± SEM values. * P < 0.05. 
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 CA-MEK1-expressing cells with simultaneous BAALC expression were resistant to 
CA-MEK1-induced differentiation, determined by flow cytometric quantification of 
CD11b and CD14 (Figure 38A and 38B).  
 
 
 
 
 
 
 
 
Figure 38. CA-MEK1-induced monocytic differentiation in HEL cells is reverted by 
additional BAALC expression. 
(A and B) Monocytic differentiation assessed by expressions of CD11b or CD14 in HEL cells 
cotransduced with BAALC and CA-MEK1. (A) Representative flow cytometric data. (B) 
Cumulative data from three independent experiments.  
Data are mean ± SEM values. * P < 0.05, ** P < 0.01. 
 
 BAALC blocked induction of differentiation-associated genes in 
CA-MEK1-expressing cells (Figure 39).  
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Figure 39. CA-MEK1-induced expression of monocytic differentiation-associated genes 
in HEL cells is reverted by additional BAALC expression. 
Expression levels of monocytic differentiation-associated genes (CES, CSF1R and MAFB) in 
HEL cells cotransduced with BAALC and CA-MEK1. Values are normalized to the expression 
levels in control vector-transduced HEL cells (n = 3).  
Data are mean ± SEM values. * P < 0.05, ** P < 0.01. 
 
 Microscopic analysis also revealed that the morphological features of monocytes seen 
in CA-MEK1-transduced cells were abrogated by concomitant BAALC expression 
(Figure 40).  
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Figure 40. CA-MEK1-induced monocytic change in HEL cells is reverted by additional 
BAALC expression. 
Representative images of May-Giemsa stained HEL cells cotransduced with BAALC and 
CA-MEK1 (scale bars, 50 µm). 
 
 The amount of KLF4 in the nucleus was reduced by BAALC in 
CA-MEK1-expressing cells (Figure 41), supporting the hypothesis that BAALC blocks 
ERK-dependent differentiation by affecting the amount of KLF4 in the nucleus. 
 
 
 
 
Figure 41. CA-MEK1- induced accumulation of KLF4 in the nucleus is canceled by 
additional BAALC expression in HEL cells. 
Immunoblotting of KLF4 in the nuclear fractions of HEL cells cotransduced with BAALC and 
CA-MEK1. 
 
 To further elucidate the role of KLF4 in BAALC-derived proliferation and 
differentiation block with prolonged ERK activation, we assessed whether 
differentiation block in HEL cells by BAALC could be reversed by additional 
expression of KLF4. As expected, KLF4 overexpression restored nuclear KLF4 
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(Figure 42A) and decreased proliferation in BAALC-expressing HEL cells (Figure 
42B).  
 
 
 
 
 
 
Figure 42. BAALC-induced proliferative advantage in HEL cells is canceled by 
additional KLF4 expression. 
(A) Immunoblotting of nuclear KLF4 in HEL cells cotransduced with BAALC and KLF4. (B) 
Growth curve of HEL cells cotransduced with lentiviruses encoding BAALC or control Venus 
and lentiviruses enco Growth curve of HEL cells cotransduced with BAALC and KLF4 (n = 
3).  
Data are mean ± SEM values. * P < 0.05. 
 
 KLF4 induced monocytic differentiation regardless of BAALC expression, 
abrogating the differentiation block caused by BAALC (Figure 43A – 43D).  
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Figure 43. Additional expression of KLF4 induces monocytic differentiation in 
BAALC-overexpressed HEL cells. 
(A and B) Monocytic differentiation assessed by expressions of CD11b or CD14 in HEL cells 
cotransduced with BAALC and KLF4. (A) Representative flow cytometric data. (B) 
Cumulative data from three independent experiments. (C) Expression levels of monocytic 
differentiation-associated genes (CES, CSF1R and MAFB) in HEL cells cotransduced with 
BAALC and KLF4. Values are normalized to the expression levels in control 
vector-transduced HEL cells (n = 3). (D) Representative images of May-Giemsa-stained HEL 
cells cotransduced with BAALC and KLF4. (scale bars, 50 µm).  
Data are mean ± SEM values. * P < 0.05, ** P < 0.01. 
 
A 
B 
C D 
 67 
 Furthermore, the mRNA expression of key regulators of cell cycle progression 
positively regulated by ERK, such as cyclin dependent kinase 6 (CDK6) and cyclin D1 
(CCND1)51, were consistently increased in BAALC-expressing HEL cells and 
decreased in Kasumi-1 cells transduced with BAALC shRNA. Meanwhile, the 
expression of cyclin-dependent kinase inhibitor 1 (CDKN1A, p21), an essential factor 
for KLF4-mediated tumor suppression as a major transactivation target of KLF452 was 
consistently decreased in HEL cells with BAALC overexpression and increased in 
BAALC-knocked-down Kasumi-1 cells (Figure 44A and 44B). These findings 
collectively indicate that BAALC promotes cell cycle progression by activating ERK 
pathway, and inhibits monocytic differentiation by inhibiting the function of KLF4 via 
nucleo-cytoplasmic translocation. 
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Figure 44. BAALC modulates mRNA expressions of downstream targets of ERK and 
KLF4. 
(A) Expression levels of downstream target genes of ERK and KLF4 (CCND1, CDK2, CDK4, 
CDK6, CDKN1A and CDKN1B) in HEL cells transduced with BAALC or control vector. 
Values are normalized to the expression levels in control vector-transduced HEL cells (n = 3). 
(B) Expression levels of CCND1, CDK2, CDK4, CDK6, CDKN1A and CDKN1B in 
Kasumi-1 cells transduced with sh_Luc. or sh_BAALC #1. Values are normalized to the 
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expression levels in control vector-transduced Kasumi-1 cells (n = 3). 
Data are mean ± SEM values. * P < 0.05. 
 
MEK/ERK inhibition in combination with KLF4 induction is a potential 
therapeutic strategy against BAALC-high AML. 
 From the above-mentioned data, it is suggested that modulating ERK pathway and 
KLF4 expression would be an attractive target for treating BAALC-high leukemia. 
Thus we established tetracycline-inducible (Tet-ON) KLF4-expressing AML cell lines, 
in which KLF4 expression is induced by doxycycline. Although the effect of U0126 on 
differentiation of BAALC-expressing cells was marginal, KLF4 induction by 
doxycycline potently induced monocytic differentiation in these cells (Figure 45).  
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Figure 45. Doxycycline-induced expression of KLF4 invoked monocytic differentiation in 
BAALC-overexpressed HEL cells. 
Cumulative data showing CD11b or CD14 expressions in HEL cells cotransduced with 
BAALC and Tet-ON KLF4 followed by treatment with U0126 (5 µM) or Dox (1 µM) or both. 
Data are mean ± SEM values. ** P < 0.01. 
  
 Given that BAALC exerts dual action on leukemia cells through ERK and KLF4, we 
evaluated the efficacy of combination therapy with MEK inhibition plus KLF4 
induction in Kasumi-1 cells. Of note, there was an additional inhibitory effect of MEK 
inhibition and KLF4 induction on cell proliferation (Figure 46A), possibly reflecting 
accelerated differentiation induced by KLF4 (Figure 46B and 46C).  
 
 
 
 
 
 
 
 
A 
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Figure 46. MEK inhibition and KLF4 induction differentially affect Kasumi-1 cells. 
(A) Growth curve of Kasumi-1 cells transduced with tetracycline-inducible (Tet-ON) KLF4 
treated with DMSO or U0126 (5 µM) combined with PBS or doxycycline (Dox; 1 µM) (n = 3).. 
(B and C) Monocytic differentiation assessed by expressions of CD11b or CD14 in Kasumi-1 
cells transduced with Tet-ON KLF4 followed by treatment with U0126 (5 µM) or Dox (1 µM) 
or both. (B) Representative flow cytometric data. (C) Cumulative data from three independent 
experiments.  
Data are mean ± SEM values. * P < 0.05, ** P < 0.01.  
 
 We next assessed the effect of MEK inhibition on the proliferation of several AML 
cell lines. Interestingly, sensitivity to MEK inhibitor was positively correlated to 
BAALC expression level (Figure 47).  
 
 
 
 
C 
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Figure 47. Correlation between BAALC expressions and sensitivities to MEK inhibitor in 
AML cell lines. 
Expression of BAALC in AML cell lines and their sensitivity to U0126 was compared and 
Pearson’s product-moment correlation coefficient was calculated. 
 
 The proliferation of AML cell lines with high BAALC (Kasumi-1, OCI-AML2) was 
effectively inhibited at 15-25 fold lower concentration of U0126 compared to cells 
with low BAALC (MV4-11, HEL) (Figure 48).  
 
 
 
 
 
Figure 48. Sensitivity to U0126 in AML cell lines. 
AML cell lines were treated with U0126 at the indicated concentrations and cell viabilities 
were determined by trypan blue exclusion assays (n = 4). IC50 value of each cell line is 
provided. 
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 BAALC expression was also positively correlated to in vitro sensitivity to U0126 
among primary human AML cells (Figure 49), highlighting MEK/ERK pathway as a 
legitimate therapeutic target in AML with high BAALC expression.  
 
 
 
 
Figure 49. Correlation between BAALC expressions and sensitivities to MEK inhibitor in 
human bone marrow cells from AML patients. 
Sensitivity to U0126 of CD34+CD38- fractions in bone marrow cells from AML patients (n = 
7) and their BAALC expression was compared and Pearson’s product-moment correlation 
coefficient was calculated. 
 
 
 Finally, we developed BAALC-high AML model mice using NOD/SCID/gamma 
(NSG) mouse to investigate the combinational effect of MEK inhibition and KLF4 
induction in vivo (Figure 50).  
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Figure 50. Schematic design of xenograft mouse models of human AML.  
A xenograft mouse model of human AML with high expression of BAALC was developed 
using NSG mice. Before transplantation, NSG mouse was treated with i.p. injection of 
cyclophosphamide. At day 0 and day 1, Kasumi-1 cells were i.v. injected. Once PB chimerism 
of leukemia cells exceeded 1 %, treatment either by U0126 or doxycycline was started. 
 
After intraperitoneal injection of cyclophosphamide for 2 days, Kasumi-1 cells 
expressing either BAALC shRNA or control shRNA were transplanted intravenously 
and the overall survival was evaluated. These xenotransplants succumbed to AML 
characterized by extensive infiltration of human CD45+ leukemia cells in the BM, the 
liver and the spleen (Figure 51A and 51B).  
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Figure 51. Establishment of xenograft mouse model. 
(A) Representative macroscopic pictures of livers and spleens from a human AML xenograft 
mouse and a normal NSG control mouse (scale bars, 1cm). (B) Microscopic analyses of the 
bone marrow, the liver and the spleen from a human AML xenograft mouse and a normal NSG 
control mouse. Hematoxylin and eosin (H&E) staining and immunohistochemical staining 
with anti-human CD45 antibody were done for each slide (original magnification 40× and 
600×, Scale bars, 200 µm in 40× and 20 µm in 600× images. Arrows in the spleen from a 
human AML xenograft mouse show hCD45+ cells.) 
 
 
 BAALC shRNA had a positive effect on mice transplanted with Kasumi-1 cells to 
prolong their survival, recapitulating the adverse prognostic impact of high BAALC 
A 
C 
B 
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expression in human AML (Figure 52).  
 
 
 
 
Figure 52. NSG mice transplanted with Kasumi-1 cells recapitulate human AML with 
high expression of BAALC. 
Overall survival of NSG mice transplanted with Kasumi-1 cells transduced with sh_Luc. or 
sh_BAALC (n = 4). 
 
 Next we transplanted Kasumi-1 cells transduced with lentiviral Tet-ON vector 
encoding KLF4 into NSG mice. After confirming the engraftment of Kasumi-1 cells in 
the peripheral blood by flow cytometry, we divided engrafted mice into four groups; 
control group, U0126 monotherapy group, doxycycline monotherapy group and U0126 
plus doxycycline combination therapy group. Compared to the modest effect of MEK 
inhibition or KLF4 induction monotherapy on overall survival, combination treatment 
of MEK inhibition plus KLF4 induction significantly prolonged the survival (Figure 
53).  
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Figure 53. MEK inhibition and KLF4 induction synergistically works against 
BAALC-high leukemia. 
Overall survival of NSG mice transplanted with Kasumi-1 cells transduced with Tet-ON KLF4 
followed by treatment with DMSO, U0126, Dox or U0126 plus Dox (n = 6). U0126 was 
administered intraperitoneally at 25 µmol/kg/week and Dox was given orally (diluted in 
drinking water at 1 mg/mL). 
  
 These findings clearly indicate that MEK inhibition combined with KLF4 induction 
would be a promising therapeutic strategy against BAALC-high AML (Figure 54). 
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Figure 54. Schematic summary of this study.  
BAALC interacts with MEKK1 in the cytoplasm and up-regulates ERK pathway as an adaptor 
protein. Constitutive activation of ERK pathway conventionally mediates monocytic 
differentiation via nuclear KLF4 accumulation. In contrast, in the presence of excess BAALC, 
KLF4 accumulation in the nucleus is blocked by cytoplasmic BAALC. Thus BAALC 
promotes leukemia cell proliferation by activating ERK pathway while blocking differentiation 
of leukemia cells by preventing ERK-pathway mediated KLF4 accumulation in the nucleus. 
This unique dual function of BAALC might contribute to a formation of more aggressive 
leukemia. 
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Discussion 
 In this study, we showed that BAALC promotes proliferation and drug resistance of 
AML cells by sustained activation of ERK pathway through the interaction with 
MEKK1 and that BAALC inhibits monocytic differentiation induced by ERK through 
nucleo-cytoplasmic translocation of KLF4. We also demonstrated that inhibition of 
ERK pathway, especially combined with KLF4 induction, is highly effective against 
BAALC-high leukemia cells both in vitro and in vivo. 
 Our detailed experiments revealed that BAALC interacts with MEKK1, inhibits 
reassociation of ERK and MKP3, and consequently maintains ERK activity, which is 
one of the pivotal transmitters of growth-factor signaling. Sustained activation of ERK 
pathway promotes proliferation through cell cycle progression in AML cells. In 
addition, ERK-dependent up-regulation of chemoresistance-associated transporters in 
response to cytotoxic agents were enhanced by BAALC overexpression, indicating that 
BAALC mediates a variety of functions on AML cells by modulating ERK activity. 
Since aberrant expressions of ABC transporters are well-known markers for poor 
prognosis in AML patients 53, 54, molecules targeting them have been extensively 
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searched, but yet to be discovered 55, 56. Considering the association of higher BAALC 
expression among AML patients with primary refractory disease and paucity of 
promising drugs in clinical use targeting these chemoresistance-associated transporters, 
the rationality of treating BAALC-high AML with MEK inhibitors to overcome 
ERK-mediated drug resistance should be emphasized. 
 Although aberrant activation of ERK pathway is implicated in the biology of AML15, 
chronic activation of ERK induced by constitutive active form of MEK1 leads AML 
cells to monocytic differentiation57, suggesting an unidentified mechanism that blocks 
ERK-mediated differentiation of AML cells. Several genes have been implicated in the 
differentiation of myeloid cells such as RUNX1, C/EBPα, PU.1 and KLF427, 58-60, but 
none have been identified as a key player in ERK-mediated differentiation of myeloid 
leukemia cells. In this report, we demonstrated that constitutively active 
MEK1-induced monocytic differentiation of AML cells depends on KLF4 induction, 
which is the other interacting partner of BAALC. In addition, we showed a unique 
spatiotemporal distribution of KLF4 in the presence of BAALC. BAALC inhibits the 
nuclear localization of KLF4 by interacting with KLF4 in the cytoplasm and hindering 
 81 
its nuclear translocation by immunofluorescence study. It is of note that mRNA 
expression levels of BAALC in AML cell lines with higher expression of BAALC 
protein utilized in our immunofluorescence study was similar to those in primary bone 
marrow cells from AML patients with high BAALC expression. Physiological 
sequestration of specific tumor suppressor proteins in the cytoplasm has been 
documented in several cases61-63 and drugs targeting this subcellular protein-protein 
interactions do exist 64, 65. To our knowledge, this is the first report that shows the 
cytoplasmic sequestration of KLF4 confers oncogenic potential. Our study also 
suggests that targeting KLF4 would be a rational choice for overcoming 
treatment-resistant BAALC-high AML. 
 Furthermore, our data indicated that MEK inhibition could effectively treat 
BAALC-high AML. Although several MEK inhibitors are already utilized in a clinical 
settings66, the efficacy of MEK inhibitor monotherapy is limited so far, firstly because 
of the high probability of side effects due to its narrow therapeutic concentration range, 
and secondly because of emergence of resistance mainly due to the complex signaling 
networks inducing up-regulation of bypass pathways and MAPK reactivation through 
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positive and negative feedback-loops66. Thus, proper and multimodal therapy is needed 
in most cases of malignancies treated by MEK inhibitors67-69. In our experiments using 
AML cell lines and primary human samples, AML cells with higher expression of 
BAALC possessed higher sensitivity to MEK inhibitor U0126. In addition, U0126 
decreased the proliferation rate of leukemia cells with high BAALC expression at 
significantly lower concentration compared to that of BAALC-low cells. These results 
suggested that AML patients with higher expression of BAALC might be effectively 
treated by MEK inhibitor at relatively low doses, which can reduce the toxicity. 
Moreover, MEK inhibitor can reverse the drug resistance conferred by BAALC, which 
might be involved in unfavorable prognosis of BAALC-high AML patients, and can 
potentiate the therapeutic efficacy of other antileukemic agents. Given that U0126 
cannot reverse differentiation block caused by direct interaction of BAALC with KLF4 
independently from ERK, KLF4 induction therapy both in vitro and in vivo was 
combined with MEK inhibition in this study. Our results clearly showed that 
concurrent MEK inhibition and KLF4 induction are highly effective for BAALC-high 
AML. Several drugs which can induce KLF4 have been evaluated in clinical and 
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preclinical settings, making our approach feasible and highly promising29.  
 To date, there have been few reports that provide a perspective on the leukemogenic 
property of BAALC itself70-73. This is the first report underscoring the uniqueness of 
BAALC to be an unprecedented dual-acting protein which functions as an adaptor 
protein in MAPK cascade and as a molecular trap against KLF4 in the cytoplasm, 
although a physiological role of BAALC as well as KLF4 is yet to be clarified. 
Considering that MEK inhibition is effective for inhibiting the proliferation and drug 
resistance of BAALC-high leukemia cells even at lower doses and concurrent KLF4 
induction further enhances therapeutic efficacy, our results strongly indicate that 
combination therapy targeting this novel BAALC-ERK-KLF4 axis would become a 
promising strategy for refractory AML with high BAALC expression. 
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Table 1 1 
 2 
PCR primers used for RT-PCR. 3 
 Forward (5’  3’) Reverse (5’  3’) 
BAALC AAGGCACCAACAGATTCA AAGGCCATTCTGTTTCTG 
CES1 GAACCACAGAGATGCTGGAGC TCCCCGTGGTCTCCTATCAC 
CSF1R GAGCGACGTCTGGTCCTATG AGGATGCCAGGGTAGGGATT 
MAFB CTCAGCACTCCGTGTAGCTC GTAGTTGCTCGCCATCCAGT 
GAPDH CATGTTCGTCATGGGGTGAACCA AGTGATGGCATGGACTGTGGTCAT 
ABCB1 CAGGAACCTGTATTGTTTGCCACCAC TGCTTCTGCCCACCACTCAACTG 
ABCC1 ACCCTAATCCCTGCCCAGAG CGCATTCCTTCTTCCAGTTC 
ABCC2 ACGGGCACATCACCATCAAG CTCCAGGCAGCATTTCCAAG 
ABCC3 CGCCTGTTTTTCTGGTGGTT TTGTGTCGTGCCGTCTGCTT 
ABCC4 GCGGCTGACGGTTACCCTCTT TCTGATGCCTTATCCCAAAAAGCAGT 
ABCC5 CCAAGCTGACCCCCAAAATGAAAAA TGGATGTGCTTGCCTTCTTCCTCTTC 
ABCG2 GGTGGAGGCAAATCTTCGTTATTAGA GAGTGCCCATCACAACATCATCTT 
CDK2 GCCAGAAACAAGTTGACGGGAGA TGGGTGTAAGTACGAACAGGGAC 
CDK4 CTGTGGACATGTGGAGTGTTG GGCAGAGATTCGCTTGTGTG 
CDK6 TGCACAGTGTCACGAACAGA ACCTCGGAGAAGCTGAAACA 
CCND1 CTTCCTCTCCAAAATGCCAG AGAGATGGAAGGGGGAAAGA 
CDKN1A GAGGCCGGGATGAGTTGGGAGGAG CAGCCGGCGTTTGGAGTGGTAGAA 
CDKN1B AGACGGGGTTAGCGGAGCAA TCTTGGGCGTCTGCTCCACA 
 4 
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Table 2 1 
 2 
Target sequences used for shRNA knockdown experiments. 3 
 5’ → 3’ 
sh_BAALC#1 GAGACTGAATTAGACCCT 
sh_BAALC#2 TCACAAAGAACTGTGTCAA 
sh_KLF4 GCTCCATTACCAAGAGCTCAT 
sh_Luc. CGTACGCGGAATACTTCGA 
 4 
